登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>CD4 >CD4-H82F3

Biotinylated Human CD4 Protein, Fc,Avitag™ (MALS verified)

分子别名(Synonym)

CD4,CD4mut,LEU3

表达区间及表达系统(Source)

Biotinylated Human CD4, Fc,Avitag (CD4-H82F3) is expressed from human 293 cells (HEK293). It contains AA Lys 26 - Pro 396 (Accession # P01730-1).

Predicted N-terminus: Lys 26

Request for sequence

蛋白结构(Molecular Characterization)

CD4 Structure

This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 69.7 kDa. The protein migrates as 90-100 kDa under reducing (R) condition, and > 180 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 0.2 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

CD4 SDS-PAGE

Biotinylated Human CD4, Fc,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

CD4 SEC-MALS

The purity of Biotinylated Human CD4, Fc,Avitag (Cat. No. CD4-H82F3) is more than 90% and the molecular weight of this protein is around 170-200 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

CD4 ELISA

Immobilized Ibalizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Human CD4, Fc,Avitag (Cat. No. CD4-H82F3) with a linear range of 0.2-6 ng/mL (QC tested).

Protocol

CD4 ELISA

Immobilized HIV-1 [HIV-1/Clade C (16055)] GP120, His Tag (Cat. No. GP5-V15224) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD4, Fc,Avitag (Cat. No. CD4-H82F3) with a linear range of 0.5-8 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-FACS

CD4 FACS

2e5 of anti-CD4 CAR-293 cells were stained with 100 μL of 1 μg/mL of Biotinylated Human CD4, Fc,Avitag (Cat. No. CD4-H82F3) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

T-cell surface glycoprotein CD4 is also known as T-cell surface antigen T4/Leu-3. CD4 contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CD4 is accessory protein for MHC class-II antigen/T-cell receptor interaction. CD4 induces the aggregation of lipid rafts. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.

 

前沿进展

Penile metastasis from colon cancer with BRAF V600E mutation treated with BRAF/MEK-targeted therapy plus cetuximab: A case report
Wu, Cheng, Lan et al
World J Gastrointest Oncol (2025) 17 (3), 100152
Abstract: The incidence of colon cancer has been progressively increasing over time, whereas penile metastasis of colon cancer has remained exceedingly uncommon. Since the prognosis for colon cancer with BRAF V600E mutation is relatively unfavorable, further exploration and investigation are still required to develop treatment strategies for such rare cases.About one year after surgery and chemotherapy, a 50-year-old patient with sigmoid colon cancer developed a mass at the base of the patient's penis, accompanied by severe tenderness and pain during urination. With disease progression, multiple metastatic nodules also emerged in other regions of the penis, including the coronal sulcus. The nodules located in the coronal sulcus were excised for histopathological examination. The histopathological findings revealed that the nodules were metastases originating from the sigmoid colon cancer, with a BRAF V600E mutation detected. This prompted a modification of the therapy regimen of cetuximab, dabrafenib and trametinib, which effectively held back the progression of penile metastasis in the patient.Combining the BRAF/MEK-targeted therapy with cetuximab demonstrates a favorable therapeutic response in BRAF V600E-mutated colon cancer with penile metastasis.©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
HER2-targeted therapy in colorectal cancer: a comprehensive review
Benli, Arıkan, Akbulut-Çalışkan
Clin Transl Oncol (2025)
Abstract: Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide. Despite treatment advancements in the last decades, CRC remains heterogeneous with significant clinical and genetic diversity. Human epidermal growth factor receptor 2 (HER2) proto-oncogene plays a critical role, as its amplification or overexpression leading to abnormal cell proliferation and tumorigenesis. HER2 overexpression or amplification is identified in 2-4% of metastatic CRCs (mCRC) patients, representing a potential therapeutic target. It is also associated with resistance against epidermal growth factor receptor (EGFR)-targeted therapies like cetuximab and panitumumab, for treatment of RAS wild-type mCRC. Although HER2-positive mCRC is rare, assessing HER2 levels is important. Furthermore, anti-HER2 therapies exhibited non-toxic profile and high efficacy in chemorefractory cases. This review delves into modern management of anti-HER2 therapies in CRC with a particular focus on recent advances and current knowledge about the prognostic and predictive value of HER2.© 2025. The Author(s).
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment
Kokori, Olatunji, Ogieuhi et al
Int J Clin Oncol (2025)
Abstract: Colorectal cancer (CRC) poses a substantial global health challenge, ranking as the third most commonly diagnosed and second most fatal cancer worldwide. With an increasing incidence, particularly in older populations, CRC demands innovative therapeutic approaches to address the limitations of existing treatments. One critical target in CRC is the KRAS gene, which is frequently mutated and implicated in various cancer-related processes. This narrative review explores the promising role of Sotorasib plus Panitumumab combination therapy in CRC treatment. Combining Sotorasib with Panitumumab, an EGFR antagonist, offers a synergistic approach to comprehensively block KRAS and EGFR pathways, potentially overcoming resistance mechanisms observed in monotherapies. The review discusses the evolution of CRC treatment from traditional chemotherapy to the advent of targeted therapies like Bevacizumab and Cetuximab. It highlights the limitations of existing therapies, including resistance and toxicities, emphasising the urgency for innovative approaches. The CodeBreak clinical trials, specifically CodeBreak 101 and CodeBreak 300, provide a focal point for evaluating the efficacy of Sotorasib plus Panitumumab in patients with refractory KRAS G12C-mutated mCRC. Preliminary results demonstrate significant improvements in progression-free survival (PFS) and objective response rates, suggesting a paradigm shift in CRC treatment. The preliminary findings from the CodeBreak 300 trial signify a transformative impact of Sotorasib plus Panitumumab in refractory KRAS G12C-mutated mCRC. With a notable increase in PFS and objective response rates and a well-tolerated safety profile, this combination therapy emerges as a potential new standard of care. The results present an optimistic outlook for patients resistant to conventional therapies.© 2025. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Dual Potential of Cetuximab Conjugated Hydroxyapatite Zirconium Nanoparticle as Nanocarrier for Radioenhancer in X-Ray Dynamic Therapy and 177Lu-based Radioimmunotherapy of Lung Cancer
Kurniawan, Mahendra, Rizaludin et al
Nanotheranostics (2025) 9 (1), 82-94
Abstract: This study aimed to synthesize cetuximab (CTX) conjugated hydroxyapatite zirconium (HApZr-CTX) as a nanocarrier for active delivery of photosensitizer and therapeutic radionuclide. The system enabled targeted radioenhancer in X-ray dynamic therapy and radioimmunotherapy for lung cancer. The results showed that HApZr-CTX had the main characteristics of hydroxyapatite crystal in X-ray powder diffraction (XRD), with particle size twice bigger, according to DLS-PSA and TEM measurements. Cellular ROS generation was elevated almost three times in A549 cells after being treated using 125 µg/mL HApZr-CTX and irradiated with 5 Gy of X-ray photon compared to untreated cells. The viability of the treated lung cancer cell line decreased after exposure to external radiation. Moreover, as a radioimmunotherapy candidate, 177Lu was successfully loaded into HApZr-CTX nanocarrier and internalized in A549 more than half of the given dose after 0.5 h incubation. [177Lu]Lu-HApZr-CTX was primarily accumulated in the lung organs of healthy mice one-hour post-injection. In conclusion, HApZr-CTX nanoparticles have the potential to be used as a radioenhancer in X-ray dynamic therapy and radioimmunotherapy for lung cancer therapy.© The author(s).
Showing 1-4 of 9352 papers.
Powered by BizGenius
 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CD4靶点信息
英文全称:T-cell surface antigen CD4
中文全称:T细胞表面抗原CD4
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:22详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定